Fig. 2From: Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndromeQOL scores comparison in IBS-D patients pre- and post-rifaximin treatment. Note: *P < 0.05, ** P < 0.01, *** P < 0.001; IBS, irritable bowel syndrome; IBS-D, diarrhea-predominant IBS; QOL, Quality of lifeBack to article page